Immatics (NASDAQ:IMTXW – Get Free Report) traded down 3.7% during trading on Thursday . The company traded as low as $2.87 and last traded at $2.89. 1,002 shares were traded during trading, a decline of 87% from the average session volume of 7,851 shares. The stock had previously closed at $3.00.
Immatics Trading Down 3.7 %
The company’s fifty day moving average price is $2.79 and its two-hundred day moving average price is $3.07.
About Immatics
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Recommended Stories
- Five stocks we like better than Immatics
- The Significance of Brokerage Rankings in Stock Selection
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Progress Software Stock Back in the Green After Beating Forecasts
- Investing in Construction Stocks
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.
